Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Down on Analyst Downgrade

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) gapped down before the market opened on Tuesday after HC Wainwright lowered their price target on the stock from $115.00 to $100.00. The stock had previously closed at $58.09, but opened at $52.15. HC Wainwright currently has a buy rating on the stock. Ionis Pharmaceuticals shares last traded at $56.7850, with a volume of 2,792,197 shares changing hands.

Several other brokerages also recently issued reports on IONS. Royal Bank Of Canada cut their price target on shares of Ionis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating for the company in a report on Monday, July 13th. JPMorgan Chase & Co. upped their price objective on shares of Ionis Pharmaceuticals from $72.00 to $76.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Morgan Stanley dropped their price objective on shares of Ionis Pharmaceuticals from $130.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, July 10th. Barclays cut their target price on shares of Ionis Pharmaceuticals from $115.00 to $90.00 and set an “overweight” rating for the company in a research note on Friday, July 10th. Finally, Wells Fargo & Company reduced their target price on Ionis Pharmaceuticals from $100.00 to $95.00 and set an “overweight” rating on the stock in a report on Thursday, July 30th. Seventeen research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $91.95.

Insider Transactions at Ionis Pharmaceuticals

In related news, Director Michael R. Hayden bought 5,000 shares of Ionis Pharmaceuticals stock in a transaction dated Friday, July 31st. The shares were bought at an average cost of $51.60 per share, for a total transaction of $258,000.00. Following the completion of the transaction, the director owned 24,000 shares of the company’s stock, valued at approximately $1,238,400. This trade represents a 26.32% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP C. Bennett sold 5,536 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $83.58, for a total transaction of $462,698.88. Following the sale, the executive vice president directly owned 75,018 shares in the company, valued at $6,270,004.44. This trade represents a 6.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 225,163 shares of company stock worth $17,711,191. Corporate insiders own 1.81% of the company’s stock.

More Ionis Pharmaceuticals News

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Analysts remain bullish despite lower targets. HC Wainwright reduced its price target from $115 to $100 while maintaining a “buy” rating, implying substantial upside from recent levels. Canaccord Genuity also kept a “buy” rating but lowered its target from $95 to $85. The reductions likely reflect greater caution following the pelacarsen setback rather than a complete loss of confidence in Ionis’ broader pipeline.
• Positive Sentiment: ZANVASTRO launch planning provides a separate potential catalyst. Ionis discussed the FDA approval and launch strategy for ZANVASTRO in Alexander disease, offering investors a commercial opportunity outside the failed pelacarsen study. Ionis discusses FDA approval and launch strategy for ZANVASTRO
• Neutral Sentiment: Broader biotech weakness amplified the move. Ionis was listed among stocks trading lower in Tuesday’s premarket session as U.S. equity futures declined. Novartis’ sharp selloff after the pelacarsen result also spread pressure across biotech companies and related partners. Biotech stocks moving lower in premarket trading
• Negative Sentiment: Pelacarsen failed its Phase 3 primary endpoint. The cardiovascular outcomes study did not demonstrate the required reduction in cardiovascular events, clouding the drug’s outlook and potentially reducing the value of Ionis’ partnered pipeline opportunity. Ionis shares fall after pelacarsen Phase 3 trial misses primary endpoint
• Negative Sentiment: Investor concerns may extend to competing cardiovascular drugs. The failure also pressured Amgen because investors questioned whether its competing olpasiran program can produce successful Phase 3 results, underscoring heightened skepticism toward cardiovascular RNA therapies. Amgen shares fall after pelacarsen misses Phase 3 goal

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System lifted its position in Ionis Pharmaceuticals by 8,029.6% during the 2nd quarter. California State Teachers Retirement System now owns 14,347,446 shares of the company’s stock valued at $1,137,609,000 after purchasing an additional 14,170,961 shares during the period. Capital World Investors grew its position in shares of Ionis Pharmaceuticals by 41.2% during the 4th quarter. Capital World Investors now owns 17,961,299 shares of the company’s stock worth $1,420,918,000 after buying an additional 5,238,571 shares during the period. Franklin Resources Inc. grew its position in shares of Ionis Pharmaceuticals by 19,941.6% during the 4th quarter. Franklin Resources Inc. now owns 1,321,345 shares of the company’s stock worth $104,532,000 after buying an additional 1,314,752 shares during the period. Baker BROS. Advisors LP raised its stake in shares of Ionis Pharmaceuticals by 216.1% during the fourth quarter. Baker BROS. Advisors LP now owns 1,791,841 shares of the company’s stock worth $141,753,000 after buying an additional 1,225,043 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in Ionis Pharmaceuticals by 7,219.3% in the third quarter. Marshall Wace LLP now owns 958,829 shares of the company’s stock valued at $62,727,000 after buying an additional 945,729 shares during the period. 93.86% of the stock is currently owned by institutional investors.

Ionis Pharmaceuticals Trading Down 3.0%

The business’s 50 day simple moving average is $60.80 and its 200-day simple moving average is $70.32. The company has a debt-to-equity ratio of 3.07, a current ratio of 7.89 and a quick ratio of 7.73. The stock has a market capitalization of $9.37 billion, a P/E ratio of -16.30 and a beta of 0.42.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.